{"id":2637,"date":"2025-01-28T16:56:15","date_gmt":"2025-01-28T13:56:15","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=2637"},"modified":"2026-03-19T10:42:50","modified_gmt":"2026-03-19T07:42:50","slug":"glucocorticoid-use-in-dmd-patients-and-impact-on-growth-effect","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/tr\/glucocorticoid-use-in-dmd-patients-and-impact-on-growth-effect\/","title":{"rendered":"DMD Hastalar\u0131nda Glukokortikoid Kullan\u0131m\u0131 ve B\u00fcy\u00fcme \u00dczerindeki Etkisi"},"content":{"rendered":"

Duchenne kas distrofisi (DMD) olarak bilinen \u00e7ocukluk \u00e7a\u011f\u0131 kal\u0131tsal bir bozukluk, artan kas zay\u0131flamas\u0131 ve bozulmas\u0131yla karakterizedir. Esas olarak erkekleri etkiler ve stabil ve g\u00fc\u00e7l\u00fc kaslar i\u00e7in gerekli olan distrofin eksikli\u011fine neden olur. DMD'li \u00e7ocuklar\u0131n s\u0131n\u0131rl\u0131 bir ya\u015fam beklentisi vard\u0131r ve s\u0131kl\u0131kla 30'lu ya\u015flar\u0131ndan \u00f6nce veya 30'lu ya\u015flar\u0131nda kalp veya solunum yetmezli\u011fi ya\u015farlar; ne yaz\u0131k ki bilinen bir tedavisi yoktur.<\/p>\n\n\n\n

DMD'nin kas-iskelet sistemi etkileri hastalar\u0131n motor becerilerini \u00f6nemli \u00f6l\u00e7\u00fcde bozar ve ya\u015fam kalitesi \u00fczerinde \u00f6nemli etkilere neden olur. Ek olarak, kemik d\u00f6n\u00fc\u015f\u00fcm\u00fcn\u00fc engelleyen kas k\u00fctlesinin azalmas\u0131ndan kaynaklanan b\u00fcy\u00fcme ve geli\u015fme bozuklu\u011fu nedeniyle k\u0131sa boy ve d\u00fc\u015f\u00fck BMI (V\u00fccut Kitle \u0130ndeksi) yayg\u0131nd\u0131r. Bu durum genellikle DMD y\u00f6netiminin temel ta\u015f\u0131 olan glukokortikoid (GC) tedavisiyle daha da k\u00f6t\u00fcle\u015fir.<\/p>\n\n\n\n

Prednizon ve deflazakort, kas g\u00fcc\u00fcn\u00fc art\u0131rmak, y\u00fcr\u00fcmeyi uzatmak, akci\u011fer fonksiyonunu iyile\u015ftirmek ve kas iyile\u015fmesine yard\u0131mc\u0131 olmak i\u00e7in iltihab\u0131 azaltmak i\u00e7in kullan\u0131lan GC tedavisinin \u00f6rnekleridir. Ancak uzun vadeli GC kullan\u0131m\u0131 b\u00fcy\u00fcme hormonlar\u0131n\u0131n \u00fcretimini engelleyebilir ve bu da bodur b\u00fcy\u00fcmeye yol a\u00e7abilir. B\u00fcy\u00fcme bask\u0131lanmas\u0131n\u0131n azalt\u0131lmas\u0131 m\u0131 yoksa desteklenmesi mi gerekti\u011fi hala tart\u0131\u015f\u0131lmaktad\u0131r.<\/p>\n\n\n\n

DMD'li Hastalarda Boy De\u011fi\u015fimlerine \u0130li\u015fkin Bulgular<\/h2>\n\n\n\n

Ara\u015ft\u0131rmalar, DMD hastalar\u0131nda b\u00fcy\u00fcme bozuklu\u011funun derecesinin GC tedavisinin t\u00fcr\u00fc, dozu ve uzunlu\u011fundan etkilendi\u011fini g\u00f6stermektedir. \u00d6rne\u011fin, DMD'nin ayakta tedavi a\u015famas\u0131nda alternatif bir prednizon rejiminin boy veya kilo \u00fczerinde fark edilebilir bir olumsuz etkisinin olmad\u0131\u011f\u0131 g\u00f6sterilmi\u015ftir. Dahas\u0131, b\u00fcy\u00fcme hormonu tedavisi g\u00f6ren DMD hastalar\u0131nda kardiyak, pulmoner veya motor yeteneklerinden \u00f6d\u00fcn vermeden artan geli\u015fim h\u0131z\u0131 g\u00f6r\u00fclm\u00fc\u015ft\u00fcr.<\/p>\n\n\n\n

\u0130lgin\u00e7 bir \u015fekilde, \u00e7al\u0131\u015fmalar DMD'li ki\u015filerin daha k\u0131sa olmaktan klinik olarak fayda sa\u011flayabilece\u011fini \u00f6ne s\u00fcr\u00fcyor. DMD'li k\u00fc\u00e7\u00fck \u00e7ocuklar y\u00fcr\u00fcyebilir, ancak ya\u015flar\u0131 ilerledik\u00e7e bu kapasiteyi kaybederler, bu da boyla birlikte i\u015flevlerin azald\u0131\u011f\u0131n\u0131 g\u00f6sterir.<\/p>\n\n\n\n

DMD'li erkek \u00e7ocuklarda boy ve klinik sonu\u00e7lar\u0131n erken bir ara\u015ft\u0131rmada \u00f6nemli \u00f6l\u00e7\u00fcde ili\u015fkili oldu\u011fu bulundu. Y\u0131llar i\u00e7inde, ilgili ara\u015ft\u0131rmalar bunu do\u011frulad\u0131 ve b\u00fcy\u00fcme inhibisyonunun DMD'nin seyrini geciktirmek i\u00e7in yararl\u0131 bir strateji olabilece\u011fini g\u00f6sterdi. Bu fenomen muhtemelen kas lifi ba\u015f\u0131na y\u00fckteki \u00fcstel art\u0131\u015f\u0131n getirdi\u011fi mekanik zorlanmadan kaynaklanmaktad\u0131r, bu da kas liflerinin kayb\u0131n\u0131 h\u0131zland\u0131r\u0131r ve yap\u0131lara zarar verir. Sonu\u00e7 olarak, kas lifleri \u00fczerindeki stresi azaltmak ve i\u015flevlerini korumak, a\u011f\u0131rl\u0131k ta\u015f\u0131mayan aktiviteler kullanarak ve kontroll\u00fc bir kiloyu koruyarak elde edilebilir.<\/p>\n\n\n\n

Hem hastalar hem de bak\u0131c\u0131lar i\u00e7in DMD belirli duygusal ve fiziksel zorluklara yol a\u00e7ar. Tedavi planlar\u0131 her hasta i\u00e7in \u00f6zelle\u015ftirilmeli, hem b\u00fcy\u00fcme \u00fczerindeki olas\u0131 etkiler hem de GC terapisinin avantajlar\u0131 dikkate al\u0131nmal\u0131d\u0131r. Hem hastal\u0131\u011f\u0131n ilerlemesini hem de ya\u015fam kalitesini hesaba katan kapsaml\u0131 bir yakla\u015f\u0131m, bilim ilerledik\u00e7e hala hayati \u00f6nem ta\u015f\u0131maktad\u0131r.<\/p>\n\n\n\n

Devam\u0131n\u0131 oku:<\/strong> FDA Onayl\u0131 DMD (Duchenne Musk\u00fcler Distrofi) Tedavileri<\/a><\/p>\n\n\n\n

Referanslar:<\/p>\n\n\n\n

    \n
  1. Duchenne kas distrofisinde k\u0131sa boy neden faydal\u0131d\u0131r?<\/a><\/li>\n\n\n\n
  2. Duchenne kas distrofisi ve glukokortikoid kaynakl\u0131 boy k\u0131sal\u0131\u011f\u0131 olan \u00e7ocuklarda b\u00fcy\u00fcme hormonu tedavisi.<\/a><\/li>\n\n\n\n
  3. Duchenne kas distrofisinde boy k\u0131sal\u0131\u011f\u0131: 34 hastay\u0131 i\u00e7eren bir \u00e7al\u0131\u015fma.<\/a><\/li>\n\n\n\n
  4. 10 g\u00fcn prednizon tedavisi alan ve 10 g\u00fcn kesilen bir dizi ayaktan Duchenne kas distrofisi hastas\u0131nda normal boy ve kilo.<\/a><\/li>\n\n\n\n
  5. Duchenne Musk\u00fcler Distrofisi olan erkek \u00e7ocuklarda b\u00fcy\u00fcme, ergenlik geli\u015fimi ve iskelet sa\u011fl\u0131\u011f\u0131.<\/a><\/li>\n\n\n\n
  6. Duchenne kas distrofisinde boy ile klinik seyir aras\u0131ndaki ili\u015fki.<\/a><\/li>\n<\/ol>","protected":false},"excerpt":{"rendered":"

    A childhood hereditary disorder known as Duchenne muscular dystrophy (DMD) is characterized by increasing muscle weakening and degradation. It mainly affects men and results in a deficiency of dystrophin, which is essential for stable and strong muscles. Children with DMD have a limited life expectancy and frequently experience cardiac or respiratory failure before or during […]<\/p>\n","protected":false},"author":1,"featured_media":2641,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[563],"tags":[211,379,209,210,212],"class_list":["post-2637","post","type-post","status-publish","format-standard","has-post-thumbnail","category-care-guidelines","tag-deflazacort","tag-dmd-care","tag-glucocorticoid","tag-prednisone","tag-steroid"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/comments?post=2637"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/posts\/2637\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media\/2641"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/media?parent=2637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/categories?post=2637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/tr\/wp-json\/wp\/v2\/tags?post=2637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}